CyBorD: stellar response rates in AL amyloidosis

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

(2012) C. P. Venner et al.   BLOOD

The repertoire of   light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44

(2011) V. Perfetti et al.   BLOOD

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

(2011) S. Madan et al.   BLOOD

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis

(2010) G. Palladini et al.   BLOOD

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

(2010) S. Dietrich et al.   BLOOD

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38  MAPK pathway

(2010) J. Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

(2008) D. Lebovic et al.   BRITISH JOURNAL OF HAEMATOLOGY